Contract

Exhibit 10.19

This amendment corrects a technical error where the reference to Section 4.4 as set forth below was incorrectly 4.2 in the original document.

CONFIDENTIALTREATMENT REQUESTED

CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN

SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION

AMENDMENT NO. 1

TO THE EXCLUSIVE LICENSE AGREEMENT

This Amendment No. 1 to the Exclusive License Agreement (the “Amendment”) is made as of this 8^th day of August, 2000, by and between Introgen Therapeutics, Inc., a Texas corporation having its principal place of business at 000 Xxxxxxxx Xxxxxx, Xxxxx 0000, Xxxxxx, Xxxxx 00000 (“Introgen”), Corixa Corporation, a Delaware corporation having its principal place of business at 0000 Xxxxxxxx Xxxxxx, Xxxxx 000, Xxxxxxx, Xxxxxxxxxx 00000 (the “Company”), and Chinook Corporation, a Delaware corporation and a wholly-owned subsidiary of the Company “Chinook,” and collectively with the Company, “Corixa”).

RECITALS

WHEREAS, the parties hereto have entered into that certain Exclusive License Agreement, effective as of July 19, 1999 (the “Agreement”); and

WHEREAS, the parties desire to amend the Agreement to correct a provision thereof to milestone payments;

NOW, THEREFORE, the parties hereby agree to amend the Agreement as follows:

AGREEMENT

1. Unless defined otherwise herein, capitalized terms used in this Amendment shall have the meanings given them in the Agreement.

2. Section 4.4(a)(viii) shall be amended by replacing it in its entirety with the following:

(viii) [***] ($[***]) within thirty (30) days following the first approval in a Major Market by a Regulatory Authority of a Licensed Product for an additional Major Indication that a human cancer (each an “Additional Major Indication”). It is understood that payments under this Section 4.4(a)(viii) shall be due for no more than three (3) Additional Major Indications, and, accordingly, the total amount due under this Section 4.4(a)(viii) shall not exceed [***] ($[***]).

*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions

3. Except as amended hereby, the Agreement shall continue in full force and effect in accordance with its terms.

4. This Amendment shall be governed by and construed under the laws of the state of Washington without giving effect to the principles of conflicts of laws.

*** Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions

2

IN WITNESS WHEREOF, each of the parties has caused this Amendment to be executed by its duly authorized representative.

CORIXA CORPORATION						INTROGEN THERAPEUTICS, INC.
By:		/s/ Xxxx XxXxxx				By:		/s/ Xxxxx X. Xxxxxx
Name:		Xxxx XxXxxx				Name:		Xxxxx X. Xxxxxx
Title:		President and COO				Title:		V.P. of Intellectual Property
CHINOOK CORPORATION
By:		/s/ Xxxx XxXxxx
Name:		Xxxx XxXxxx
Title:		President